Pharmafile Logo
Pharmafocus logo
Advanced Search

J&J

Showing 15 posts of 219 posts found.

kris-sterkens-23052017-hr-1

Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA

April 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma

Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …

Feature
shutterstock_274590824

J&J pays out $37m in damages over claims its talc contains asbestos

April 6, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …

News
dominic_caruso

J&J’s longest-standing CFO finally steps down

March 21, 2018
Medical Communications, Research and Development J&J, JJ, Johnson & Johnson, biotech, cfo, drugs, pharma, pharmaceutical

Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from …

News
jj

J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

February 15, 2018
Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer

Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma

It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …

News

FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer

February 9, 2018
Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …

News

J&J’s apalutamide shows strength in non-metastatic prostate cancer

February 7, 2018
Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 26, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate

As we come to the end of January, it’s Friday again – time for another rundown of the top ten …

News
shutterstock_92671375

US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …

News
jj_sign_on_wall

J&J withdraws controversial vaginal mesh from Australian market

January 23, 2018
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, pharma, vaginal mesh

Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all …

News
darzalex

NICE meets Janssen halfway over Darzalex

January 18, 2018
Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical

NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …

News
xarelto_10_tablet1

Bayer and J&J successfully reverse $28 million Xarelto court payout

January 10, 2018
Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten

Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …

News
4420456374_64a3d7e6aa

Pharmafile.com’s top ten stories of 2017

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023